Search clinical trials for: Itepekimab (SAR440340)

Total 13 results

Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Turkey, United States, Chile, Czechia, Israel, Russian Federation, Argentina, Brazil, Bulgaria, Canada, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway and more
Sanofi

Completed

Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe

Chronic Obstructive Pulmonary Disease

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD (AERIFY-3)

Chronic Obstructive Pulmonary Disease

United States, Netherlands, Belgium, Denmark, Germany, United Kingdom, Brazil
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Chronic Obstructive Pulmonary Disease

Bulgaria, China, United States, Argentina, Chile, Czechia, Georgia, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, United Kingdom, Mauritius
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Bronchiectasis

Spain, United Kingdom, Israel, Japan, Turkey, Chile, United States, Canada, Denmark
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Bulgaria, Chile, China, Czechia, Hungary, Israel, Poland, Taiwan, Canada, Portugal, United Kingdom, Korea, Republic of, Japan, Slovakia, South Africa
Sanofi

Terminated

First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

Leukaemia

United States, France
Sanofi

Recruiting

Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus (APATURA)

Systemic Lupus Erythematosus

Chile, Brazil, Greece, Italy, Spain, United States, Argentina, Hungary, Mauritius, Mexico, Russian Federation, Turkey, Ukraine, Puerto Rico, Switzerland
Sanofi

Active, not recruiting

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Multiple Sclerosis

Bulgaria, Canada, Turkey, Spain, United States, Czechia, France, Germany, Russian Federation, Ukraine
Sanofi

Completed

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) (phaethuSA)

Sjogren's Syndrome | Sjögren's Syndrome

Belgium, Taiwan, Korea, Republic of, United States, Argentina, Canada, Chile, France, Germany, Hungary, Mexico, Spain
Sanofi
Regeneron Pharmaceuticals

Completed

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Ukraine, Argentina, Chile, Poland, Russian Federation, Turkey, United States, Australia, Canada, Germany
Sanofi

Completed

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

Healthy Volunteers

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Asthma

Ukraine, United States, Argentina, Chile, Mexico, Poland, Russian Federation, Turkey

Search clinical trials for: Itepekimab (SAR440340)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations